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Abstract
The human immunodeficiency virus type 1 (HIV-1) exterior envelope glycoprotein, gp120, possesses conserved binding sites
for interaction with the primary virus receptor, CD4, and also for the co-receptor, generally CCR5. Although gp120 is a major
target for virus-specific neutralizing antibodies, the gp120 variable elements and its malleable nature contribute to evasion
of effective host-neutralizing antibodies. To understand the conformational character and immunogenicity of the gp120
receptor binding sites as potential vaccine targets, we introduced structure-based modifications to stabilize gp120 core
proteins (deleted of the gp120 major variable regions) into the conformation recognized by both receptors.
Thermodynamic analysis of the re-engineered core with selected ligands revealed significant stabilization of the
receptor-binding regions. Stabilization of the co-receptor-binding region was associated with a marked increase in on-rate
of ligand binding to this site as determined by surface plasmon resonance. Rabbit immunization studies showed that the
conformational stabilization of core proteins, along with increased ligand affinity, was associated with strikingly enhanced
humoral immune responses against the co-receptor-binding site. These results demonstrate that structure-based
approaches can be exploited to stabilize a conformational site in a large functional protein to enhance immunogenic
responses specific for that region.
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Introduction
Effective vaccines are an extremely important means to control,
and even eradicate (e.g., smallpox) global human pandemics caused
by viral and bacterial pathogens (reviewed in [1] and [2]). A major
correlate of effective anti-viral vaccines is the elicitation of virus-
neutralizing antibodies in vaccinated individuals. With approxi-
mately 60 million humans infected with HIV-1 overall, the well-
documented global pandemic has resulted in a huge burden of
human mortality and morbidity, highlighting the need for an
effective vaccine. Structure-based development of HIV-1-specific
drugs has been enormously successful, and the application of
structure-guided vaccine design is an appealing avenue to advance
such efforts (reviewed in [3]). Here, we describe a novel effort to
applystructuralandthermodynamicanalysis toinformthe designof
vaccine immunogens that induce HIV-1-neutralizing antibodies.
The HIV-1 infection process begins with interaction of the
exterior component of the trimeric envelope glycoprotein (Env)
complex, gp120, with the primary receptor protein, CD4, present
on the host cell surface. Interaction of the Env complex (or
functional spike) with CD4, induces exposure of or formation of
the co-receptor-binding site on gp120 and enables this glycopro-
tein to bind chemokine receptor molecules (usually CCR5 or,
alternatively, CXCR4) expressed on the surface of a subset of
CD4+ lymphocytes (reviewed in [4]). These receptor-induced
activation events are followed by fusion of the viral and host cell
membranes, mediated by the transmembrane glycoprotein, gp41.
It is this series of HIV-1 Env-receptor interactions that are the
major focus of research aimed at developing broadly neutralizing
antibodies to interrupt the entry process. It is anticipated that if
such antibodies can be elicited, they will contribute a major
component to protection by an HIV-1 vaccine.
CD4 induces extensive conformational alterations in monomer-
ic gp120 as characterized by unusually large entropic changes
following gp120-CD4 interaction and by changes in antigenicity
[5–9]. The flexible gp120 glycoprotein likely presents multiple
conformations to the immune system that are not present on the
functional spike [5]. In addition, gp120 possesses conserved
antigenic determinants that, in principle, might elicit antibodies
capable of neutralizing a broad array of HIV-1 isolates. However,
gp120 variable regions and non-neutralizing determinants tend to
dominate the elicited immune response [10,11]. Moreover,
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tional masking in the context of the functional spike (i.e., epitope
inaccessibility; see [12] and reviewed in [13]) make this
glycoprotein a difficult target for broadly neutralizing antibodies
[12,14,15]. The receptor-binding structures of gp120 are con-
served among diverse viral isolates and represent functionally
constrained regions that might serve as targets of broadly
neutralizing antibodies. However, structural evidence suggests
that, within functional spike, the CD4-binding site (CD4bs) is a
recessed pocket and the co-receptor-binding site (or CD4-induced
region) is either not formed or not exposed until gp120 engages
CD4 on target cells [16].
In animal models, passive administration of neutralizing
antibodies inhibits HIV-1 infection [17–20], demonstrating the
proof-of-principle that, if elicited by a vaccine, such antibodies
could effectively inhibit viral entry. Typically, effective anti-viral
vaccines consist of either live-attenuated or chemically inactivated
forms of a given virus. These vaccines usually elicit neutralizing
antibodies as a major component of a protective response [2].
However, neither of these approaches has been successful to
prevent HIV-1 infection in a safe or effective manner. Much effort
has therefore focused on utilizing the HIV-1 envelope glycopro-
teins as recombinant, subunit vaccines to elicit potent neutralizing
antibodies. Due to the aforementioned Env variability, here we
focused on eliciting antibodies against the functionally and
structurally conserved receptor-binding regions of gp120.
Several studies attempted to elucidate the biophysical factors of
the antigen that effect the maturation of host antibody responses
[21,22]. However, no study to date has tested the impact of
conformational stabilization and increased ligand affinity on
enhancing the immune responses against discrete conformational
regions in the context of a large functional protein. Here, we test
the concept that conformational fixation of the conserved
receptor-binding sites on the surface of gp120 would enhance
elicitation of antibody responses against those target sites. The
approach is based upon the high-resolution crystal structures of
core gp120 protein in a ternary complex with CD4 and the co-
receptor mimetic, CD4-induced (CD4i) antibody, 17b, and the
unliganded SIV core structure [16,23]. The structural informa-
tion, consistent with the thermodynamic analysis, indicates that
major structural rearrangements occur within gp120 following
interaction with CD4 [23]. Previously, we exploited this
information to design core gp120 molecules with up to 50%
stabilization of the CD4bs, and one such protein, Ds12F123, was
co-crystallized with the broadly neutralizing anti-HIV-1 antibody,
b12 [24]. However, limitations in protein expression prevented us
from introducing additional stabilizing mutations into this
molecule to achieve greater conformational stabilization.
In the present study, we re-designed the core gp120, based upon
new available structures [25], to enhance protein folding and
expression, and layered upon this, additional mutations to stabilize
the CD4-binding site as well as the co-receptor-binding region.
Detailed conformational characterization of the receptor-binding
sites of these modified proteins are presented. We tested the effects
of the stabilizing mutations in regards to the elicitation of
antibodies in small animals. We demonstrate that the novel
mutagenic stabilization of a discontinuous epitope, typified by an
increased on-rate of ligand binding to this region, dramatically
increased the immunogenicity and neutralizing capacity of elicited
antibodies specific for that epitope region.
Results
gp120 Core Redesign Permits the Introduction of Four
Stabilizing Cysteine Pairs
To focus the immune response onto the conserved receptor-
binding sites, it is important to remove immunodominant regions,
such as the V1/V2 and V3 hypervariable loops. Previously, loop
truncations demonstrated that such removal was possible; however,
structural analysis suggested more optimal designs were feasible
[16,25,26]. For example, the structure of core gp120 with intact V3
loop showed that the previouslypublished Gly-Ala-Gly substitution of
V3 residues 298–329 (to accomplish deletion of V3) removed four
hydrogen-bonds from b-strand 12 and five hydrogen-bonds from b-
strand 13 [25]. We modeled a new substitution (V3S) that retained
these hydrogen bonds, and added a longer linker (Figure 1A). Further
structural analysis indicated that additional trimming of the flexible
V1V2 loop to eliminate a naturally occurring cysteine pair might
facilitate accommodation of additional pairs of stabilizing cysteines
elsewhere in the molecule. Accordingly, a more minimal loop (V1/
V2b) was modeled with a type II turn connecting strands b2a n db3,
replacing nine residues (CVGAGSCNT) with an Ala-Gly-Ala tri-
peptide (see Figure 1).
To reduce conformational flexibility and lock core gp120 into its
receptor-bound state, we used two tactics: filling hydrophobic pockets
and adding inter-domain disulfides. We previously described cavity-
filling or ‘‘F mutations’’ to fill the Phe-43 pocket (where critical
contacts are made for CD4 binding) and other gp120 cavities
[24,27,28], and also described the introduction of inter-domain
cysteine pairs (disulfides or Ds mutations) [24]. Here, we used a
combination of loop alterations, F mutations and Ds mutations, to
create four new immunogens. The ‘‘coreV3S’’ contained the V1/
V2b and V3S alterations. Meanwhile ‘‘2CC’’, ‘‘3CC’’ and ‘‘4CC’’
involved 2, 3 and 4 additional inter-domain disulfides, in concert with
the gp120 cavity-filling mutations (F1, F2 and/or F3; Figure 1B and
1C). We also expressed two previously described immunogens, core
and Ds12F123 [24], as controls. The new designs resulted in the
expression of well-folded gp120 proteins as assessed by their
interactions with conformational ligands 17b and b12 (see below).
Protein purity and molecular mass were determined by SDS-PAGE
analysis followed by Coomassie blue staining (Figure S1).
Variable Loop Structural Elements Influence Formation of
the Receptor-Binding Sites
The purified proteins were tested for recognition by ligands
directed against the receptor binding sites, first by ELISA
Author Summary
Vaccination is an effective means to control worldwide
human diseases caused by viruses and other pathogens.
Most viral vaccines work by inducing the immune system
to generate neutralizing antibodies. The human immuno-
deficiency virus (HIV) continues to cause huge tolls in
terms of human death and disease. The generation of
neutralizing antibodies against HIV remains a key but
elusive goal for the development of an effective vaccine.
Here, we describe a novel approach that uses atomic-level
structures of the HIV surface protein, gp120, together with
extensive biophysical analysis of this protein, to design
modified vaccine candidates. Immunization with these
modified gp120 proteins revealed a new relationship
between structure-guided protein stability and the effi-
cient elicitation of antibodies against the highly conserved
co-receptor binding site of HIV. These data demonstrate
the potential for using the design principles established
here to develop improved antibody-generating HIV
vaccines and for vaccines against other pathogens.
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mutations in Ds12F123 enhanced affinity for CD4 binding over
that of the parent core protein. Interestingly, the coreV3S protein
displayed slightly increased CD4 affinity even without any
additional stabilizing modifications, suggesting that the V1V2b
and V3S modifications influence formation, stability or accessibil-
ity of the CD4 binding region on the gp120 core. Addition of
stabilizing mutations to coreV3S protein, however, did not
increase the already high affinity binding of CD4 to the modified
proteins. We also assessed recognition of the proteins by b12, a
CD4bs-directed antibody that recognizes a surface similar to but
not identical with that of CD4 [24]. The core and the coreV3S
proteins both displayed similar recognition by b12, suggesting that
the modified truncations of the V1V2- and the V3 loop did not
impact upon b12 binding. However, addition of the stabilizing
mutations affected b12 binding to different degrees irrespective of
the core context (see Figure 2). These findings are consistent with
our earlier observation that the same set of stabilizing mutations
reduce b12 affinity to some degree [24]. However, the greater
impact of the stabilizing mutations on b12 affinity observed in this
study may be a result of the coreV3S protein context or, for the
ELISA, by the detection reagent used (i.e., rabbit sera raised
against the unmodified core gp120 protein).
We then tested effects on the gp120 co-receptor-binding site
assessed by recognition of the cores by the co-receptor mimetic
antibody, 17b [6]. As expected, the original core gp120 protein
was not recognized by 17b, in contrast to the partially stabilized
Ds12F123 protein (which possesses 2 pairs of cysteines; see also
[24]). However, the V3S modifications facilitated increased
recognition by 17b (closed circles) even in the absence of CD4
or stabilizing mutations. Incorporation of 2, 3 or 4 cysteine pairs
did not alter the avid recognition of the coreV3S protein by 17b as
determined by ELISA (Figure 2A). These results indicated that
somewhat unexpectedly, the V3S structural elements play a
critical role in the formation of the 17b-associated co-receptor-
binding site.
We also determined effects of the structural alterations on the
recognition of gp120 by ligands that bound outside the CD4 and
co-receptor regions. We selected the monoclonal antibody 2G12,
which binds to a conformational glycan epitope on the outer
domain of gp120 that is distal from the CD4bs. The 2CC protein
displayed slightly reduced affinity whereas the 3CC and 4CC
proteins showed somewhat increased affinity for 2G12. These
small but unanticipated differences in affinities were not
contributed by differences in the amounts of proteins used since
equal protein quantities were confirmed by both optical density
and SDS gel analysis (data not shown).
Stabilizing Mutations Affect Ligand Affinity to the Co-
Receptor Site by Increased On-Rate
Since the putative stabilizing mutations influenced recognition
by the receptor-site-directed ligands, we performed SPR studies to
identify the contributions of the individual rate constants in
regards to the changes in affinity for these ligands. As shown in
Figure 2B, the on-rates (ka) of CD4 binding to the stabilized cores
remained nearly unchanged relative to the unmodified core.
However, there was a subtle and gradual decrease in off-rates
upon addition of the cysteine pairs, leading up to twofold increase
in CD4 affinity (10.5 nM for coreV3S versus 5.5 nM for 4CC).
For b12 binding, the on-rates were significantly reduced for the
stabilized proteins as reflected in the overall affinities. For the
kinetic analysis of 17b binding (Figure 2C), we included the core
protein (without the V3S modifications) to determine the influence
of V3S modification on the antigenicity of the co-receptor-binding
site. The core protein was recognized by 17b with extremely low
affinity, which was not detectable in the ELISA format (see also
Figure 2A). In stark contrast, the newly designed coreV3S protein
is recognized by 17b with remarkably high affinity (3 nM), even in
the absence of CD4. Addition of the stabilizing mutations did not
alter the off-rates of 17b interaction to any of the coreV3S
variants. However, the on-rates increased significantly, ranging
from increases of 11- (for 2CC) to 27- (for 3CC) to 18-fold (for
4CC) over the on-rate observed for 17b binding to coreV3S.
Therefore, the enhancement of 17b affinity for the series of V3S-
stabilized cores was directly correlated with an increase in the on-
rate of antibody binding.
To investigate the influences of CD4 interaction with gp120 on
17b binding in the coreV3S protein context, the V3S protein
variants were pre-incubated with 10-fold molar excess of sCD4
and the protein mixtures were then analyzed by SPR. As expected,
the previously crystallized core protein showed high affinity
(28 nM) binding to 17b in the presence of CD4, with nearly
undetectable affinity in the absence of CD4. Note, however, that
the coreV3S displayed nanomolar affinity even in the absence of
CD4, implicating greatly the V3S modifications on stabilization of
the 17b epitope, and perhaps the bridging sheet itself (see Figure 1
and [16]). The association rate constant for 17b binding to
coreV3S was increased 10-fold in the presence of CD4, resulting
in nearly a 10-fold increase in the observed affinity. The 2CC
protein exhibited only a 1.5-fold gain in the on-rate of 17b binding
and a 2.5-fold increase in overall 17b affinity in the presence of
CD4. For cores containing the 3CC or 4CC mutations, pre-
incubation with CD4 did not alter 17b affinity, suggesting that the
3CC and 4CC mutations mimic closely the conformational effects
induced by CD4 relative to formation or stabilization of the co-
receptor-binding site.
Thermodynamic Analysis Confirms Mutagenic
Stabilization of the CD4–Binding Site and the Co-
Receptor Binding Region
To evaluate the extent of stabilization of the receptor-binding
sites on gp120, we performed isothermal titration calorimetry
(ITC) and determined the apparent change in enthalpy (DH) and
entropy (2TDS) upon binding of coreV3S variants to the primary
receptor, CD4, or to the co-receptor mimetic antibody, 17b. The
Figure 1. Structural elements of the HXBc2 gp120 core protein and its stabilized derivatives. A. Amino acid sequences of the V1/V2 loop
and the V3 loop as present in full-length gp120, in the previously crystallized core protein and in coreV3S protein. Linker sequences are in lower case.
B. Linear diagram of core and coreV3S derivatives showing positions of V1/V2- and V3 loop deletions, cavity-filling mutations (F, teal arrows) and
paired disulfide mutations (Ds, green dotted lines). The schematics depict surface models of each corresponding core derivative indicating relative
positions of the mutations within inner domain (blue) and outer domain (red). C. Ribbon diagram of HXBc2 core gp120 crystal structure with all
stabilizing mutations modeled on it. Indicated are the modifications of V1V2- and V3 loops (labeled dashed lines), the CD4 binding surface
(translucent gray), the 17b epitope surface contacts (yellow) and the beta strands comprising the bridging sheet sub-domain (purple). Note the
proximity of Ds2 and Ds3 to both the CD4 binding site and the bridging sheet. 17b is the prototypic co-receptor-binding-site-directed antibody,
which inhibits gp120-CD4 interaction with co-receptor, and serves as surrogate for co-receptor N-terminal interaction with the gp120 core.
Conserved V3 loop elements (not shown) also contribute to gp120-CD4-co-receptor interaction.
doi:10.1371/journal.ppat.1000445.g001
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PLoS Pathogens | www.plospathogens.org 4 March 2009 | Volume 5 | Issue 5 | e1000445Figure 2. Antigenic analysis of unmodified and structurally stabilized core envelope variants by ELISA and SPR. A. ELISA plates were
coated with ligand (2 mg/ml), reacted with 5-fold serial dilutions of affinity-purified envelope glycoproteins (starting at 5 mg/ml) and detected with
1:2500 dilution of rabbit immune sera raised against HXBc2 core protein (unmodified). Upper left, binding to soluble human CD4 (4-domain;
gp120 Stability and Immunogenicity
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measured in the two possible orders: A and B (Figure 3A). In order
A, CD4 was combined with gp120 (A1), followed by 17b binding to
the gp120-CD4 complex (A2); in order B, 17b was combined with
gp120 (B1), followed by CD4 binding to the gp120-17b complex
(B2). The thermodynamic values of these interactions are
summarized in Figure 3B and 3C. In A1 reactions, the enthalpy
of CD4 interaction was approximately 56 kcal/mol for the
coreV3S protein and approximately 27 kcal/mol for each of the
mutants, indicating that approximately 50% less bond formations/
reformations and/or solvent displacement occurred when the
stabilizing mutations were present. This observation was support-
ed by approximately 65% reduction in change in entropy for the
mutants (approximately 16 kcal/mol) compared to the coreV3S
protein (45 kcal/mol), indicating that the mutations substantially
stabilized the coreV3S protein into the CD4-bound conformation.
Interestingly, the calculated entropy values were similar for all the
mutants, suggesting that Ds12F123 mutations, present in 2CC,
account for most of the effect in stabilizing the CD4-binding
region. In A2 reaction, addition of 17b to the coreV3S-CD4
Figure 3. Thermodynamic values of sCD4 and 17b interactions with gp120 variants measured by ITC at 37uC. A. Schematic of complete
thermodynamic cycles showing two possible orders of reactions. B and C. Changes in enthalpy (DH), entropy (2TDS) and free energy (DG) upon
ligand interactions with gp120. B. Binding to CD4 (A1) followed by binding to 17b (A2). C. Binding of 17b (B1) followed by binding to CD4 (B2).
doi:10.1371/journal.ppat.1000445.g003
Progenics); upper right, binding to b12; lower left, binding to 17b; lower right, binding to 2G12. Margins of error from duplicate wells were negligible
in all cases. B and C. Binding rate constants for interactions of stabilized gp120 core proteins with sCD4, b12 and 17b. Approximately 500 RU each of
17b, sCD4 and b12 were coated on CM5 chip. Two-fold serial dilutions of each gp120 protein were allowed to bind to the surfaces for 3 min followed
by dissociation for 5 min. The kinetic constants were obtained by fitting the curves to 1:1 Langmuir binding model. B. Kinetics of CD4 and b12
interactions. C. Kinetics of 17b binding to gp120 variants without or with pre-exposure to 10-fold molar excess of sCD4. *Data obtained from very low
binding interaction (maximum RU of 8.5).
doi:10.1371/journal.ppat.1000445.g002
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accounted by an entropy change of 17.5 kcal/mol. However,
entropy of this interaction was significantly decreased by the
stabilizing mutations in 2CC and 3CC, indicating that besides
stabilizing the CD4-binding site, the structure-guided mutations
further stabilized the co-receptor-binding site in a manner beyond
that achievable by interaction with CD4 itself.
To measure the effects of the mutations on stabilizing the co-
receptor-binding site, the 17b antibody was titrated with each
envelope variant (B1 reactions). 17b binding to the coreV3S yielded
approximately 52 kcal/mol of favorable enthalpy and approximate-
ly 40 kcal/mol of change in compensating unfavorable entropy,
suggesting that 17b binding alone can induce similarly large
conformational (and/or solvation) effects to the gp120 core. The
stabilizing mutations reduced the enthalpy change during the B1
reaction by almost 50%. Consistent with these data, we observed as
wella significant decreaseinthe entropy change inthe presenceof 2,
3 or 4 pairs of cysteines, leading up to 75% reduced entropy for 17b
interaction as compared to the ,40 kcal/mol value obtained for
17b-coreV3S. These results indicated that the selected mutations
significantly stabilized the conformation of the co-receptor-binding
site. We then measured the thermodynamics of CD4 binding to
these gp120-17b complexes (B2 reactions). CD4 binding to
coreV3S-17b complexes resulted in a 17.3 kcal/mol of entropy
change. However, the entropy value of CD4 binding to 17b
complexes with 2CC, 3CC or 4CC proteins, each containing the
respective stabilizing mutations, did not change relative to the
parental protein. The entropy of CD4 binding to gp120-17b
complexes (approximately 16 kcal/mol) therefore perhaps resulted
from reduced flexibility of gp120 elements distal from the CD4-
binding pocket, and/or from solvent effects. The B2 reactions also
showed less negative DG values in the presence of the stabilizing
mutations, suggesting that 17b alone can induce a most thermody-
namically favorable conformation of the CD4-binding site, and
presence of the current set of stabilizingmutations actually conferred
a slightly negative impact on the 17b-induced CD4-binding region.
Stabilization Selectively Enhances Immunogenicity of the
Co-Receptor Binding Region
The kinetic and thermodynamic characterizations of the
coreV3S envelope variants revealed considerable stabilization of
both the CD4bs and the co-receptor binding site, associated
particularly with enhanced on-rate and affinity by 17b. Therefore,
we tested impact of these modifications on elicitation of antibody
responses in vivo. To allow better statistical analysis, we immunized
14 rabbits with each protein immunogen. The overall immune
response after each inoculation was analyzed by ELISA to
measure IgG binding to either core or to coreV3S proteins. In
all cases (except for BSA), high titers of anti-gp120 antibodies were
detected after two inoculations, with end-point titers reaching
1.5610
5 (Figure S2). The binding titers did not substantially
increase with additional inoculations.
After four inoculations, we sought to analyze the overall breadth
of HIV neutralization elicited by these immunogens. Due to the
large number of sera, we screened the neutralization activity at a
1:5 dilution of each serum against viruses pseudotyped with clade
B (9 isolates) or clade C (1 isolate) or clade A (1 isolate) HIV-1
envelope glycoproteins. The results, shown as percent neutraliza-
tion of viral entry, are summarized in Figure 4. Autologous
(HXBc2) neutralization was achieved by all sera. Interestingly,
although the breadth was somewhat limited, the 3CC and 4CC
stabilized V3S immunogens elicited a trend of higher neutraliza-
tion responses against several primary HIV-1 clade B isolates,
namely SF162, SS1196 and ADA (a typically neutralization-
resistant isolate), and a clade C isolate, MW965 when compared to
responses elicited by the coreV3S (Figure 4). In addition, we
analyzed core and Ds12F123 proteins (lacking the V3S modifica-
tions) for immunogenicity and obtained similar results to the V3S
equivalents (Figure S3). Because percent neutralization is a rough
approximation of the actual inhibitory titer, we confirmed these
data by deriving inhibitory dilution 50% values (ID50) of all sera
for selected isolates (HXBc2, SS1196 and MW965; see Figure S4).
Since the cysteine-based mutagenesis resulted in significant
stabilization and enhanced ligand affinity of the co-receptor-
binding site, we employed an assay which detects the presence of
functionally active antibodies specific for the co-receptor binding
site that is conserved between HIV-1 and HIV-2 (see Figure 5A
and Methods; [29]). Most sera elicited by coreV3S demonstrated
little cross neutralization of the HIV-2 isolate (see Figure 5A).
However, in stark contrast, very potent HIV-2 neutralization
responses were elicited by the stabilized core immunogens, 3CC
and 4CC. Moderate neutralization was elicited by the 2CC
immunogen. In the 3CC and 4CC elicited sera, we observed low-
titer and inconsistent neutralization of SF162, SS1196 and ADA
that parallels the more consistent neutralization of a particular
clade C HIV-1 isolate, MW965, and the HIV-2 isolate,
7312AV434M, by these sera. Interestingly, both of the latter two
isolates are known to be sensitive to co-receptor binding site-
directed antibodies under the conditions tested.
Following the initial neutralization analysis at a single dilution of
the sera, we determined ID50 values of all immune sera against the
indicator HIV-2 isolate (Figure 5A). Compared to the non-stabilized
coreV3S, the stabilized proteins elicited significantly more potent
HIV-2 neutralizing responses in the order of 4CC.3CC.2CC.
coreV3S. The linear regression analysis of the HIV-2 neutralization
titers and corresponding immunogen properties (ligand affinity, on-
rate of ligand binding and stabilization of the 17b epitope) showed
distinct linear correlations in all cases (Figure 5B).
In a parallel immunogenicity study, performed in guinea pigs,
the V3S or 3CC modifications were introduced into a DNA
prime, recombinant adenovirus (rAd) regimen in a gp120 core
context or in the previously described gp145DCFI and
gp140DCFI contexts (Figure S5, panel A; [30]). High serum titers
of HIV-2 cross-neutralizing antibodies were detected in guinea
pigs that were inoculated with the 3CC-containing DNA/rAd
immunogens only (Figure S5, panel B).
Next, we examined the effects of conformational stabilization on
the elicitation of antibodies to the CD4 binding region. Since there is
no HIV neutralization assay available yet to specifically map serum
immune responses against the CD4bs, we performed competition
ELISA experiments with CD4 as previously described (Figure S6;
[28]). We also established a similar competition assay with the CD4bs
antibody, b12, based upon our observation that the presence of excess
17b antibody does not affect the binding of b12 to the coreV3S
protein (Figure S7). Results from both competition assays indicated
that all three of the stabilized immunogens elicited CD4bs-directed
antibodies, although, in particular instances, to lesser extents
compared to the coreV3S immunogen. Therefore, the modest
neutralization capacity elicited by the coreV3S variants (Figure 4)
indicated that if we have elicited neutralizing antibodies against the
CD4 binding region, they are not of the breadth or potency of b12 or
CD4itself.Thesedatawereconsistent withbindinganalysisfollowing
the differential adsorptions on selected sera described below.
Stabilization Shifts the Elicited Antibody Binding and
Neutralization Specificity
The HIV-1 HXBc2 gp120 variants coreV3S and 4CC proteins,
elicited strikingly different levels of CD4i antibodies as determined
gp120 Stability and Immunogenicity
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derived from immunized animals from both the coreV3S and the
4CC group potently neutralized the autologous virus, HXBc2. We
therefore sought to characterize the target specificity of the elicited
neutralizing antibodies. We performed differential adsorption of
antibody subpopulations from each serum in a previously
described process [31,32], followed by binding analysis and
neutralization assays as described below. Due to the necessity to
adsorb out all binding antibodies in this process by gp120 protein
excess, this is not a high throughput assay in hyper-immune
animals. Therefore, immune sera from one coreV3S-immunized
rabbit and one 4CC-immunized rabbit were selected for the
analysis. The sera were incubated with Dynabeads covalently
conjugated with one of the following indicator proteins:
gp120WT, to adsorb out all gp120-directed antibodies;
gp120D368R, to adsorb out all but CD4bs-directed antibodies,
and gp120I420R, to adsorb out all but CD4i antibodies. Following
selective adsorptions, performed in gp120 excess, the flow-
throughs from these reactions were first analyzed by ELISA to
verify completion of adsorption and to determine relative
prevalence of each antibody type (Figure 6A). Complete
adsorption in each reaction was confirmed by the lack of binding
of the adsorption flow-throughs (FT; containing non-adsorbed
antibodies) to the same protein target that was attached to the
corresponding beads. The titers of either CD4bs-directed
antibodies or co-receptor-binding site-directed antibodies were
determined from binding of corresponding depleted serum to
gp120WT protein. The coreV3S protein elicited much higher titer
of CD4bs-directed antibodies than CD4i antibodies (Figure 6A,
left panel), and the conformationally stabilized 4CC protein
dramatically shifted this response towards eliciting much higher
CD4i antibodies than CD4bs-directed antibodies (right panel).
Figure 4. Neutralization profile of fivefold diluted rabbit immune sera tested against a panel of HIV-1 and HIV-2 isolates. All sera
tested were collected after four inoculations. Neutralization by preimmune sera was used as negative control for serum reactivity.
doi:10.1371/journal.ppat.1000445.g004
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[32]) is subject to less off-target effects than are cross-competition
assays and is a more definitive means to map binding specificities
delineated by selected gp120 point mutations.
Next, the potency of the selectively adsorbed immune sera
fractions was tested in selected neutralization assays. The coreV3S
protein elicited low levels of CD4i binding site antibodies
(Figure 6A, left panel), but the serum did not neutralize HIV-2
(Figure 6B, left panel). In contrast, only the CD4i antibody
population (gp120 I420R FT) of the 4CC-immunized sera
potently neutralized the HIV-2 isolate (Figure 6B, right panel)
and, as well, the highly 17b-sensitive clade C isolate, MW965
(Figure 6C, bottom panel). Similarly, only the CD4i antibody
population in the 4CC serum neutralized yet another HIV-1 clade
B isolate, SS1196, but the potency of neutralization observed
under the experimental conditions used here was relatively low
(data not shown).
The same adsorbed immune serum fractions were then
analyzed in an HXBc2 neutralization assay. This sensitive isolate
is neutralized by both non-potent CD4bs-directed antibodies and
by the non-potent co-receptor-binding-site-directed antibodies. As
shown in Figure 6C, left panel, coreV3S immune serum mediated
neutralization of HXBc2 mostly by CD4bs-directed antibodies
(gp120D368R FT), the first time elicitation of antibodies of such
specificity by an Env-based immunogen has been demonstrated.
Analysis of serum ID50 values (Figure S3) indicated that the 3CC
protein trended toward the elicitation of slightly higher HXBc2
neutralization titers than those elicited by the 4CC protein while
the potency of HIV-2 neutralization was reversed between these
groups. The data are another indication that the stabilizing
Figure 5. Statistical correlation of HIV-2 neutralization titers with kinetic and thermodynamic properties. A. ID50 values of HIV-2
neutralization by rabbit immune sera, performed in the absence and presence of sCD4. The statistical significance (p value) of the increase in HIV-2-
neutralization titer (in the presence of sCD4) with the increase in the number of stabilizing cysteines (2CC, 3CC, 4CC) was analyzed by Mann-Whitney
test. B. Linear regression analysis showing correlations of HIV-2-neutralization titer with kinetic and thermodynamic parameters. Left, with reciprocal
of affinity (1/kD); middle, with reciprocal of the association rate constant (1/ka); right, with the percent of epitope stabilization, as measured from the
entropy change (2TDS) relative to that of coreV3S.
doi:10.1371/journal.ppat.1000445.g005
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PLoS Pathogens | www.plospathogens.org 9 March 2009 | Volume 5 | Issue 5 | e1000445Figure 6. Percent neutralization of pseudotyped HIV isolates by differentially adsorbed flow-through fractions of rabbit immune
sera. A. ELISA experiments to determine gp120-binding titers of serum fractions following selective adsorptions. Immune sera from the unmodified
(coreV3S) and the most-stabilized (4CC) immunogen groups were incubated with uncoated dynal beads (blank) or dynal beads coated with BSA or
gp120WT or gp120-D368R or gp120-I420R proteins. Starting at 11-fold dilution, fivefold serial dilutions of the FTs, from these reactions were tested
for binding to gp120 on ELISA plates. Untreated serum or serum FTs from reactions with blank beads and were used as positive controls and FTs after
gp120 Stability and Immunogenicity
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proteins.
Discussion
Due to the pressing need for an effective HIV-1 vaccine, and
due to the limits of current Env-based immunogens to elicit
neutralization breadth, we pursued HIV-1 Env structure-guided
immunogen design to determine if this line of investigation will
better elicit virus neutralizing antibodies. Here, we demonstrate
that the structure-based redesigning of the HIV-1 envelope core
glycoprotein increased folding and expression of a series of related,
mutagenically stabilized molecules. Structure-guided protein
design led to stabilization of both the CD4-binding site and the
co-receptor-binding region of gp120. The data clearly demon-
strated that thermodynamic stabilization of the co-receptor-
binding site was associated with a marked increase in the on-
rate of binding of the co-receptor mimetic, 17b antibody.
Furthermore, when immunized into small animals, stabilization
of the gp120 core resulted in a dramatic enhancement of the
functional antibody response against the CD4-enhanced co-
receptor binding region shared by HIV-1 and HIV-2. These
results suggest that, in general, specific regions of an immunogen
might be rendered more immunodominant by direct conforma-
tional stabilization (in this case, cysteine-pair mutagenesis) of that
region resulting in reduced entropy. These results are appealing
from a thermodynamic perspective, as the ligand affinity (DG) can
be more favorable with a reduction in entropy (2TDS). This
thermodynamic relationship would predict that if a given epitope
(or circumscribed region) is pre-fixed into a desired conformation,
a ligand (i.e.,17b or perhaps a ‘‘naı ¨ve’’ B cell receptor) specific for
that site will not be required to initiate ‘‘induced-fit’’ [33] and will
therefore bind to the site with an increased on-rate [34].
Potentially, the overall affinity may increase (assuming no negative
impact on the off-rate), and in regards to the B cell receptor, a
faster on-rate may enhance epitope recognition, resulting in more
efficient activation of that B cell. The finding described in this
study, demonstrate that conformational stabilization of a discrete
protein region can alter the quantity and quality of the antibody
response to that protein region. They suggest that ligand
stabilization or improved ligand affinity, especially ligand on-rate,
might be used as parameters to focus functional antibody
responses on specific regions on the surface of a complex,
conformationally sensitive and multi-epitope protein.
Recently we reported that the elicitation of co-receptor-directed
antibodies is dependent upon interaction of gp140 glycoprotein
immunogens with endogenous primate CD4 molecules [35]. A
mechanism for this important observation is provided in this
current study as we clearly demonstrate that mutagenic stabiliza-
tion of g120, in a similar manner to that achieved by CD4 binding,
locks the co-receptor-binding-site into a single conformation that is
well recognized by the naı ¨ve B cell repertoire in rabbits. This
principle might be applicable for viruses that undergo receptor-
induced conformational changes to accomplish entry, and for
which a vaccine is lacking (e.g., Ebola). Deletion of immunodo-
minant variable regions of Env-based anti-viral subunit vaccines
may also have broader applicability.
The protein redesign described here to improve expression
revealed some interesting observations relative to recognition by
the 17b antibody and implications on the bridging sheet in the
coreV3S context. Our earlier data indicated that the previously
crystallized core protein could not bind 17b unless induced by
CD4 [16]. In this study, the previously described core protein was
modified at the base of the V3 loop and at the base of the V1V2
loop. Somewhat unexpectedly, we observed that the newly
designed coreV3S protein was recognized by 17b with very high
affinity even in the absence of CD4, and that CD4 binding affinity
of this protein was markedly improved. A plausible explanation of
this modified antigenicity is that restoration of the b12 and b13
strands on the outer domain indirectly aids in formation of
bridging sheet elements that are critical for 17b recognition.
Restoration of these strands may also impart stability at the base of
the Phe 43 cavity, located above (CD4 binding site, see Figure 1).
These implications are somewhat in conflict with the unliganded
SIV core structure, which shows the bridging sheet b-strands in a
non-CD4-bound orientation, but perhaps represent differences in
the structural elements present between core and coreV3S
proteins and/or differences between HIV and SIV [23]. However,
these data are consistent with the initial analysis of 17b
recognition, which revealed that 17b binds well to full-length
gp120 possessing the V3 loop, but not at all to a V3-loop deleted
protein [6], confirmed by our recent studies [28,35]. Complete V3
loop deletion was performed in the original HIV-1 and SIV
crystallized cores proteins. However, because interaction of CD4
with V3 loop-deleted gp120 completely restores 17b binding, this
suggests that CD4 can compensate for the (artificial) instability of
the bridging sheet region imparted by full truncation of the V3
stem. Yet unresolved, then, is the structure of the receptor-binding
sites in the context of the static functional spike (i.e., pre-receptor
bound state). The data described above are consistent with the
model that the co-receptor-binding site can exist in the context of
the static viral spike, but accessibility to antibody is limited unless
steric constraints are reduced by receptor engagement.
In previous studies, we have shown that the Phe 43 cavity-filling
mutations partially lock gp120 into the receptor/co-receptor-
bound conformation [24,28]. To achieve greater stabilization, we
added two pairs of cysteines and additional cavity-filling mutations
to core gp120 [24] and analyzed the thermodynamic effects of
these mutations on core gp120. Interestingly, we showed clearly
that 17b itself can stabilize gp120 into the conformation
recognized by CD4 (B1 reactions) and that the Ds mutations
used in this study have no further effect on this conformation (B2
reactions). However, it is noteworthy that, a relatively constant
amount of entropy change (15.1 to 17.3 kcal/mol) was always
detected upon addition of CD4 to gp120-17b complexes
irrespective of the presence of the stabilizing mutations. We
assume that this entropy is either accounted for stabilization of
elements distal from the cysteine pairs themselves or, alternatively,
results from some unanticipated solvent displacement effects.
Increases in 17b affinity or increased stabilization of the 17b
epitope alone were not always associated with all differences in the
immunogenicity described here. For example, between 2CC and
3CC, increased 17b affinity correlated very significantly with
increased elicitation of CD4i antibodies, although the degree of
stabilization achieved was similar in these immunogens. In
contrast, the increase in 17b affinity was minimal from 3CC to
4CC, although there was a substantial difference in epitope
stabilization. This difference correlated with the enhanced
incubation with gp120 beads were used as negative controls for binding. B. Neutralization of HIV-2 7312/V434M isolate by immune sera FTs following
differential adsorptions. Neutralization was performed in the presence of 0.5 mg/ml of soluble CD4 (sCD4). C. Neutralization of the HIV-1 clade B
isolate, HXBc2 (top panels) and the clade C isolate, MW965 (bottom panel). Margins of error obtained from duplicate reactions were negligible.
doi:10.1371/journal.ppat.1000445.g006
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and epitope stabilization both contributed to the overall altered
immune responses elicited by the current set of immunogens.
The same set of mutations that stabilized the co-receptor-
binding site also stabilized the CD4bs, generally considered a more
desired target of the study design because of the neutralization
capacity of both CD4 itself and of the CD4bs antibody, b12. In
fact, we clearly demonstrate the elicitation of CD4bs antibodies
both by ligand cross-competition and by selective adsorption.
However, the unmodified cores appear to elicit this type of activity
more efficiently than the stabilized cores (see Figure 6A, Figure S6
and Figure S7). It might be that the stabilization process itself
subtly altered the CD4-binding surface on gp120 and actually
reduced cross-reactivity with natural sequences found on the virus.
Alternatively, the stabilized CD4i site perhaps became immuno-
dominant and out-competed CD4bs-directed responses. Further-
more, although stabilization of the CD4bs, relative to its starting
entropy, approached that of the co-receptor-binding site, the
absolute values of CD4-related entropy and affinity did not.
Analysis of the sera from one representative animal immunized
with coreV3S group compared to one representative animal
immunized with the 4CC protein demonstrated a shift of antibody
response towards the 17b epitope, correlating with the increased
17b affinity. Consistent with these results, immunization studies
using synthetic peptide immunogens indicate that the kinetics of
antigen recognition influence epitope-driven repertoire selection
and antibody maturation [22]. Achieving slower ligand off-rate
may have the potential to improve immune response, although
that property may not always be approachable by structure-based
design and might be dependent upon the context. This might be in
part due to the uncertainty of the factors that define which
elements on the surface of a complex protein are most
immunogenic. It was suggested that all accessible domains on
the surface of a multi-determinant antigen can potentially induce
primary B cell responses [36]. However, only those that interact
with naive B cells with high affinity will generate an avid antibody
response [37].
Here, we demonstrate in this complex model system that it is
conformational fixation, associated with increased 17b on-rate and
overall affinity, which drives the elicitation of functionally cross-
neutralizing antibodies directed toward the gp120 co-receptor
binding region. This class of antibodies was extensively studied for
their unique properties of posttranslational tyrosine sulfation and
preferential VH gene usage [38,39]. Although to date there are no
identified co-receptor binding-site-directed monoclonal antibodies
that potently neutralize diverse primary isolates, our recent study
implicates antibodies with specificities to this site contribute to
neutralization in broadly reactive HIV-1 patient sera [32]. CD4-
induced antibodies were also associated with partial control of
SHIV challenge in macaques [40]. In the current study, the
stabilized immunogens elicited moderate neutralization responses
against a few Tier 1 HIV-1 isolates that are typically sensitive to
antibodies directed to the gp120 variable loop 3, a component
absent in the immunogens tested here. Additional analysis may be
warranted to determine if the neutralization activity observed in
selected sera is indeed mediated by CD4-induced antibodies as
was determined here for the Tier 1 isolates, MW965 and SS1196.
Thus, the co-receptor-binding region, usually occluded on most
primary isolates, remains an intriguing target due to its
conservation, especially if there exists an as yet-to-be-defined
subset of antibodies that can access elements of this region on
circulating isolates. In addition to CD4-induced responses, the
principle established in this study may have important implications
for proper stabilization of the CD4bs to generate more broadly
cross-reactive and neutralizing antibodies to this heavily shielded,
receptor-binding region towards the development of a broadly
protective HIV-1 vaccine. Beyond HIV-specific vaccine develop-
ment, the viral envelope glycoprotein and its ligands under study
here provide a model system to establish ‘‘proof-of-principle’’
regarding targeted immunogenicity. Such principles may extend
to the design of vaccines against other pathogens capable of
humoral immune evasion.
Materials and Methods
Molecular Modeling
To design a more optimal V3 truncation, hydrogen bonding at
the V3 base was examined in the gp120 core with V3 structure
(PDB ID 2B4C). To preserve observed hydrogen bonds, additional
residues between the last residue in the b12-strand and the first in
the b13-strand were retained. To design a shortened V1/V2
truncation, type II turns were modeled onto strands b2 and b3t o
determine the shortest that preserved full b2-hydrogen bonding to
strand b21. Lastly, to determine where stabilizing disulfide bonds
might be introduced into the gp120 core structure, a distance
matrix between all C ?b atoms was calculated [41]). All Cb inter-
domain pairs with distances between 3–6 A ˚ were analyzed with
explicit modeling disulfide pairs, using the interactive software
provided by the program ‘‘O’’ [42].
Protein Production
Plasmids for the expression of HXBc2 gp120 core and
Ds12F123 proteins have been described before [43]. Plasmids
expressing other immunogens (listed in Figure 1B) were derivated
either by Quick change PCR mutagenesis (for 3CC and 4CC) or
by de novo gene synthesis (coreV3S and 2CC). All immunogen
proteins were expressed in serum-free medium by transient
transfection of HEK293T cells and purified over antibody
columns as described earlier [28]. The core protein was purified
over b12 affinity column and all proteins with V3S modifications
were purified over 17b affinity columns as was the Ds12F123
protein. Expression and purification of proteins used in serum
adsorption analyses have been described elsewhere [31,32].
ELISA
The antigenicity of WT and mutant envelope proteins (Figure 2)
and the anti-gp120 antibody titers in immunized sera were
determined by ELISA analyses as described in Dey et el., 2007 [28].
Isothermal Titration Calorimetry (ITC)
All ITC reactions were performed at 37uC as described in Dey
et al., 2007 [28]. The concentration of gp120 in the sample cell
was approximately 4 mM and that of sCD4 or 17b in the syringe
was approximately 40 mM. The molar concentrations of the
proteins were calculated using the following molar extinction
coefficients: core, 1.35; Ds12F123, 1.4; coreV3S, 1.33; 2CC, 1.5;
3CC, 1.5; 4CC, 1.5; sCD4, 0.93 and IgG17b, 1.47. The specific
activity of sCD4 and 17b was determined as described previously
[28,44]. The values for enthalpy (DH), entropy (DS), and the
association rate constant (Ka) were obtained by fitting the data to a
nonlinear least-squares analysis with Origin software. For the
second step of a two-step reaction, gp120 concentration was
recalculated as per the final volume at the end of the first reaction,
which is equal to the sample cell volume plus the total volume of
the first injectant. Before the second titration, the sample volume
equivalent to the volume of the first injectant was removed from
the sample cell.
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All kinetic reactions were performed at RT on a Biacore3000
surface plasmon resonance spectrometer. To prepare binding
surfaces with approximately 500 RU per cell, ligands (7 mg/ml in
10 mM NaOAc, pH 5.5 buffer) were immobilized on CM5 chip
by the amine coupling method following manufacturer’s protocol.
The reference cell received only NaOAc buffer. Analytes were
serially diluted in the HEPES-EP reaction buffer at concentrations
ranging from 6.2 nM to 400 nM for sCD4 and b12 or 6.2 nM to
50 nM for 17b. Association was allowed for 3 min at 30 ml/min.
To determine 17b binding in the presence of CD4, gp120 dilutions
were pre-incubated for 30 min at RT with 10-fold molar excess of
2-domain sCD4. Dissociation was determined by washing off
bound analyte over the next 5 min. The chip surface was
regenerated with two injections (60 sec each) of 10 mM Glycine,
pH 3.0. The kinetic rate constants were obtained by fitting the
curves to 1:1 Langmuir binding model using BIAevaluation
software.
Animal Immunization
Approximately 12 weeks old female New Zealand White rabbits
were inoculated with 50 mg of affinity-purified protein formulated
in GlaxoSmithKline Adjuvant System AS01B, injected intramus-
cularly by splitting the protein-adjuvant mix in the two hind legs at
4 weeks intervals. Serum was collected 8–10 days after each
inoculation. Serum preparation and heat inactivation of comple-
ment systems were performed as described earlier [28]. All rabbits
were housed and maintained in the AAALAC-accredited
BIOCON, Inc (Rockville, MD) under specific pathogen-free
conditions. All experiments were approved by the Animal Care
and Use Committee of the Vaccine Research Center and
BIOCON, Inc.
Virus Neutralization Assays
Production and neutralization of pseudotyped HIV-1isolates
were described earlier [10,28,31]. To control for non-specific
effects in the assay, preimmune sera, BSA-AS01B-immunized
antisera and a pseudovirus expressing murine leukemia virus
envelope were analyzed [28,45]. Neutralization of HIV-2 strain
7312A/V434M was performed in the presence of non-neutralizing
levels of sCD4 and analyzed as previously described [28,29].
Serum Adsorptions
Antibody populations directed towards the CD4bs or the CD4i
sites were separated by absorbing rabbit immune sera on protein-
coated dynabeads as previously described [31]. In brief, sera were
diluted between 1:4 and 1:20 in DMEM/10% FBS and 1000 mlo f
diluted sera was incubated with 500 ml of beads at room
temperature for 30 minutes, followed by a second adsorption
with 250 ul of beads. After serum adsorption, beads were removed
with a magnet followed by centrifugation and were stored in PBS/
0.2%BSA/0.02% sodium azide buffer at 4uC.
Supporting Information
Figure S1 Reducing SDS-PAGE of unmodified and stabilized
core glycoproteins. All glycoproteins shown except the original core
were purified by 17b affinity chromatography. The core was
purified by b12 affinity chromatography because it is poorly
recognized by17b.The17bantibodyselectsfora hyperglycosylated
form ofthemodifiedcore variants,inpart accounting fortheslightly
slower migration of the 17b-purified glycoproteins in the gel.
Found at: doi:10.1371/journal.ppat.1000445.s001 (2.33 MB TIF)
Figure S2 Binding titers of sera from rabbits immunized with
envelope variants as determined by ELISA. Affinity purified
coreV3S protein (2 mg/ml) was coated on ELISA plates, reacted
with fivefold serial dilutions of different immune sera and detected
with anti-rabbit IgG-peroxidase conjugated secondary antibody.
Arrows indicate end point titers, defined as the last reciprocal
serum dilution at which the optical density signal was greater than
twofold over the signal detected with the preimmune sera. A.
Comparison of titers following two, three and four inoculations of
coreV3S protein. B. Comparison of titers among different groups
of immune rabbit sera following four inoculations.
Found at: doi:10.1371/journal.ppat.1000445.s002 (1.82 MB TIF)
Figure S3 Neutralization profile of fivefold diluted rabbit
immune sera tested against a panel of HIV-1 and HIV-2 isolates.
All sera tested were collected after four inoculations. Neutraliza-
tion by preimmune sera was used as negative control for serum
reactivity.
Found at: doi:10.1371/journal.ppat.1000445.s003 (1.84 MB TIF)
Figure S4 Neutralization ID50 titers of selected HIV-1 isolates
by Env-immunized rabbit anti-sera.
Found at: doi:10.1371/journal.ppat.1000445.s004 (1.65 MB TIF)
Figure S5 Elicitation of CD4i antibodies in guinea pigs following
immunization with stabilized core variants. A. Schematic
representation of immunogens used. B. IC50 titers of HIV-2
neutralization by guinea pig sera collected after 4 inoculations.
Found at: doi:10.1371/journal.ppat.1000445.s005 (1.90 MB TIF)
Figure S6 ELISA analysis comparing inhibition of sCD4
binding to envelope glycoprotein by various groups of rabbit
immune sera (im.s.) collected after four inoculations. A. Validation
of the sCD4-inhibition assay. ELISA plates coated with core
gp120 (2 mg/ml) protein were preincubated with fivefold dilutions
of rabbit immune sera or ligands, reacted with 0.8 mg/ml of sCD4
followed by biotinylated guinea pig IgG anti-CD4, and detected
with HRP-conjugated streptavidin. BSA-immunized rabbit serum
and WTgp120-immunized rabbit serum were used as negative and
positive control respectively for serum interactions. Unlabeled
IgGb12 and IgG17b were used as controls for ligand binding.
Binding of sCD4 in presence of the lowest concentration of BSA-
immunized serum was considered 100%. Margins of error from
duplicate wells were negligible. A. Validation of the sCD4-
inhibition assay. B. Range of residual sCD4 binding to coreV3S
protein in the presence of the highest concentration (20-fold
dilution) of various immune sera. Values obtained were normal-
ized against 100% binding in the presence of 2500-fold diluted
BSA-immunized sera. The horizontal lines indicate mean values
with standard errors of mean (SEM) for each group of sera. C.
Same as in B except blocking of CD4 binding by each group of
sera was detected with the corresponding protein immunogen
coated on ELISA plate.
Found at: doi:10.1371/journal.ppat.1000445.s006 (1.51 MB TIF)
Figure S7 ELISA analysis comparing inhibition of b12 binding
to coreV3S protein by various groups of rabbit immune sera
(im.s.). ELISA plates, coated with 2 mg/ml of protein, were
preincubated with fivefold dilution of rabbit immune sera or
ligands for 45 min at RT, reacted with biotinylated b12
(0.056 mg/ml of final concentration; M. Roederer, Conjugation
of monoclonal antibodies, August 2004; http://www.drmr.com/
abcon) for 30 min at RT and detected with 1:250 dilution of HRP-
conjugated streptavidin. BSA-immunized rabbit serum was used
as negative control and either full-length gp120 (WTgp120)-
immunized rabbit serum (panel A; Dey et al., 2007) or coreV3S-
immunized rabbit serum (animal ID# 4; Panel B) were used as
gp120 Stability and Immunogenicity
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IgG17b were used as positive and negative controls respectively for
ligand binding. Binding of b12 in the presence of the lowest
concentration (2500-fold dilution) of BSA-immunized serum was
considered 100%. Margins of error from duplicate wells were
negligible. A. Validation of the b12-inhibition assay. B. Inhibition
of b12 binding to coreV3S protein by immune sera tested over a
range of dilution. C. Relative b12 binding to coreV3S protein in
the presence of the highest concentration (20-fold dilution) of
various immune sera. The dotted horizontal line indicates 100%
b12 binding in the presence of 2500-fold diluted BSA-immunized
sera. The mean values of b12 binding with standard errors of
mean (SEM) for each group of sera are shown. Seven sera from
coreV3S group and nine sera from each of 2CC, 3CC and 4CC
groups were tested.
Found at: doi:10.1371/journal.ppat.1000445.s007 (2.39 MB TIF)
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